重组人表皮生长因子治疗外伤性鼓膜穿孔疗效观察

Therapeutic effect of recombinant human epidermal growth factor in the treatment of traumatic tympanic membrane perforation

目的探讨重组人表皮生长因子(rhEGF)治疗外伤性鼓膜穿孔的临床疗效。方法本研究为前瞻性研究,选择南宁市第一人民医院耳鼻咽喉头颈外科2015年1月至2018年8月期间收治的90例外伤性鼓膜穿孔患者为研究对象,根据随机数表法分为观察组(n=46)和对照组(n=44),对照组常规予等待自愈疗法治疗,观察组则应用rhEGF治疗,疗程4周,比较两组患者的临床疗效。结果治疗后,观察组患者的治疗有效率为95.65%,明显高于对照组的77.27%,差异有统计学意义(P<0.05);观察组患者的平均愈合时间为(12.4±3.1) d,明显短于对照组的(18.9±4.4) d,差异均有统计学意义(P<0.05)。两组患者均无感染等并发症发生。结论重组人表皮生长因子治疗外伤性鼓膜穿孔,可以有效促进鼓膜愈合,提高临床疗效,且具有较好的用药安全性。

Objective To investigate the clinical efficacy of recombinant human epidermal growth factor(rhEGF)in the treatment of traumatic tympanic membrane perforation.Methods In a prospective study,45 patients with traumatic tympanic membrane perforation,who admitted to Department of Otorhinolaryngology and Head and Neck Surgery between January 2015 and August 2018,were selected and divided into the observation group(n=46)and the control group(n=44)according to random number method.The control group was treated for healing therapy,and the observation group was treated with rhEGF,with the clinical course of 4 weeks.The efficacy of two groups were compared.Results After treatment,the effective rate of treatment group was 95.65%,which was significantly higher than 77.27%of the control group(P<0.05);the average healing time in the observation group was(12.4±3.1)d,which was significantly shorter than(18.9±4.4)d in the control group(P<0.05).There were of no infection and other complications occurred in the two groups.Conclusion Recombinant human epidermal growth factor can effectively promote the healing of tympanic membrane,improve the clinical efficacy,and have good medication safety.